Rasdegafusp Alfa · DEC-205, CDX-1401

What is Rasdegafusp Alfa?

Rasdegafusp alfa is a fusion protein made of a fully human monoclonal antibody against the endocytic dendritic cell receptor DEC-205, linked to the tumor-associated antigen NY-ESO-1. The antibody moiety binds DEC-205 on dendritic cells, delivering NY-ESO-1 for processing to stimulate a cytotoxic T-lymphocyte response against NY-ESO-1-expressing cells. It is studied in fallopian tube carcinoma, ovarian carcinoma and primary peritoneal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

DEC-205, CDX-1401

Drug type

Fusion protein

Targets

DEC-205 (endocytic dendritic cell receptor) (LY75)

Mechanism

Immune activation, directed at DEC-205 (endocytic dendritic cell receptor) (LY75)

Pathways

dendritic cell endocytic internalization and antigen processing, cytotoxic T-lymphocyte response

Therapy area

Oncology

In trials of

CLDX

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

SU9AMV39DB

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT02166905

Updated Oct 11, 2026.